by | Jan 13, 2026 | Diamond, Michael, Fremont, Daved, Hui, Sean, Li, Pengfei
— Published date: 1/14/2026
Value Proposition: Entry receptors that bind directly to TBEV, promoting virus attachment to treat TBEV and other viruses.
Technology Description
Researchers at Washington University in St. Louis have developed LRP8 soluble decoy receptors (minimal domains-Fc fusion …
by | Jan 13, 2026 | Diamond, Michael, Palakurty, Sathvik, Raju, Saravanan, Sariol, Alan
— Published date: 1/14/2026
Value Proposition: Soluble engineered decoy receptor protein that on its own can be used to treat multiple alphavirus types.
Technology Description
Researchers at Washington University in St. Louis have developed a composition of matter that consists of a mutagenized c…
by | Jan 13, 2026 | Chong, Zhenlu, Diamond, Michael, Fremont, Daved, Hui, Sean
— Published date: 1/14/2026
Value Proposition: First antiviral treatment that uses soluble receptors to treat yellow fever.
Technology Description
Researchers at Washington University in St. Louis have developed new soluble receptor decoy Fc-fusion protein inhibitors for treatment of yellow fever…
by | Sep 17, 2025 | Oiknine, Liam, Tang, Abby, Urano, Fumihiko
— Published Date: 8/5/2025
Value Proposition: Disease severity scoring system that can predict the progression of Wolfram syndrome.
Technology Description
Researchers at Washington University in St. Louis have developed a genotype-based severity scoring system to predict the onset of cardinal sym…
by | May 13, 2025 | Haller, Gabriel, Li, Chengcheng, Weihl, Conrad
— Published Date: 5/14/2025
Value Proposition: Method that uses gene-therapy to detect limb-girdle muscular dystrophy (LGMD) type 4R/2E.
Technology Description
Researchers at Washington University in St. Louis have developed a method of predicting limb-girdle muscular dystrophy (LGMD) type 4R/2…